Cerebrospinal fluid polyamines in patients with Glioblastoma multiforme and anaplastic astrocytoma.
Eighteen cerebrospinal fluid polyamine determinations in 12 patients with glioblastoma multiforme and 76 determinations in 37 patients with anaplastic astrocytoma were evaluated. Cerebrospinal fluid polyamine levels showed no significant relationship to the degree of malignancy or to enhanced tumor volume or volume of tumor central low density as determined by contrast-enhanced computerized tomography. A significant correlation was found between polyamine levels and the proximity of the tumor to the cerebral ventricles. Polyamine levels were correlated with clinical status as determined by neurological examination, radionuclide scan, and computerized tomography. Compared with those of stable patients, cerebrospinal fluid polyamine levels were significantly elevated in patients with recurrent tumors; however, elevation of polyamine levels did not appear to precede tumor recurrence. A large fraction of the results were false-positive or false-negative results. In contrast to our findings in patients with medulloblastoma, it appears that cerebrospinal fluid polyamine levels determinations may be of little use for monitoring tumor progression in patients with glioblastoma multiforme and anaplastic astrocytoma.
D001254:Astrocytoma / Q000134:cerebrospinal fluid* / Q000473:pathology; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid* / Q000473:pathology; D005189:False Positive Reactions; D005909:Glioblastoma / Q000134:cerebrospinal fluid* / Q000473:pathology; D006801:Humans; D009336:Necrosis; D011073:Polyamines / Q000134:cerebrospinal fluid*; D014057:Tomography, X-Ray Computed
D011073:Polyamines